<DOC>
	<DOCNO>NCT02827032</DOCNO>
	<brief_summary>To perform post-market surveillance evaluate performance MobiusHD System subject primary resistant hypertension .</brief_summary>
	<brief_title>Controlling Lowering Blood Pressure With MobiusHD™</brief_title>
	<detailed_description>The CALM-DIEM Trial open-label , prospective , multicenter study patient select treatment MobiusHD .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<criteria>Mean 24hour systolic ABPM ≥130 mmHg follow least 30 day stable antihypertensive medication regimen ( change medication dose ) , 28 day prior implantation . Known clinically suspect baroreflex failure autonomic neuropathy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Hypertension</keyword>
</DOC>